Left ventricular assist device as bridge to recovery for anthracycline-induced terminal heart failure

Jon M Appel; Kåre Sander; Peter Bo Hansen; Jacob E Møller; Anders Krarup-Hansen; Finn Gustafsson

doi:10.1111/j.1751-7133.2012.00291.x

Left ventricular assist device as bridge to recovery for anthracycline-induced terminal heart failure

Jon M Appel, Kåre Sander, Peter Bo Hansen, Jacob E Møller, Anders Krarup-Hansen, Finn Gustafsson

15 Citationer (Scopus)

Abstract

Anthracycline treatments are hampered by dose-related cardiotoxicity, frequently leading to heart failure (HF) with a very poor prognosis. The authors report a case of a 19-year-old man developing HF after anthracycline treatment for Ewing sarcoma. Despite medical treatment, his condition deteriorated to terminal HF, leading to implantation of a mechanical left ventricular assist device (LVAD). His heart function recovered, allowing explantation of the device 14 months after implantation. Heart transplantation is often contraindicated in the first years after treatment for cancers, and LVAD as "bridge to recovery" may be warranted in similar patients.

Originalsprog	Engelsk
Tidsskrift	Congestive Heart Failure
Vol/bind	18
Udgave nummer	5
Sider (fra-til)	291-4
Antal sider	4
ISSN	1527-5299
DOI	https://doi.org/10.1111/j.1751-7133.2012.00291.x
Status	Udgivet - 2012

Adgang til dokumentet

10.1111/j.1751-7133.2012.00291.x

Citationsformater

@article{70dae2daf98545b3a3d9aadf2bc9f385,

title = "Left ventricular assist device as bridge to recovery for anthracycline-induced terminal heart failure",

abstract = "Anthracycline treatments are hampered by dose-related cardiotoxicity, frequently leading to heart failure (HF) with a very poor prognosis. The authors report a case of a 19-year-old man developing HF after anthracycline treatment for Ewing sarcoma. Despite medical treatment, his condition deteriorated to terminal HF, leading to implantation of a mechanical left ventricular assist device (LVAD). His heart function recovered, allowing explantation of the device 14 months after implantation. Heart transplantation is often contraindicated in the first years after treatment for cancers, and LVAD as {"}bridge to recovery{"} may be warranted in similar patients.",

author = "Appel, {Jon M} and K{\aa}re Sander and Hansen, {Peter Bo} and M{\o}ller, {Jacob E} and Anders Krarup-Hansen and Finn Gustafsson",

note = "{\textcopyright} 2012 Wiley Periodicals, Inc.",

year = "2012",

doi = "10.1111/j.1751-7133.2012.00291.x",

language = "English",

volume = "18",

pages = "291--4",

journal = "Congestive Heart Failure",

issn = "1527-5299",

publisher = "LeJacq Communications, Inc",

number = "5",

}

TY - JOUR

T1 - Left ventricular assist device as bridge to recovery for anthracycline-induced terminal heart failure

AU - Appel, Jon M

AU - Sander, Kåre

AU - Hansen, Peter Bo

AU - Møller, Jacob E

AU - Krarup-Hansen, Anders

AU - Gustafsson, Finn

PY - 2012

Y1 - 2012

N2 - Anthracycline treatments are hampered by dose-related cardiotoxicity, frequently leading to heart failure (HF) with a very poor prognosis. The authors report a case of a 19-year-old man developing HF after anthracycline treatment for Ewing sarcoma. Despite medical treatment, his condition deteriorated to terminal HF, leading to implantation of a mechanical left ventricular assist device (LVAD). His heart function recovered, allowing explantation of the device 14 months after implantation. Heart transplantation is often contraindicated in the first years after treatment for cancers, and LVAD as "bridge to recovery" may be warranted in similar patients.

AB - Anthracycline treatments are hampered by dose-related cardiotoxicity, frequently leading to heart failure (HF) with a very poor prognosis. The authors report a case of a 19-year-old man developing HF after anthracycline treatment for Ewing sarcoma. Despite medical treatment, his condition deteriorated to terminal HF, leading to implantation of a mechanical left ventricular assist device (LVAD). His heart function recovered, allowing explantation of the device 14 months after implantation. Heart transplantation is often contraindicated in the first years after treatment for cancers, and LVAD as "bridge to recovery" may be warranted in similar patients.

U2 - 10.1111/j.1751-7133.2012.00291.x

DO - 10.1111/j.1751-7133.2012.00291.x

M3 - Journal article

C2 - 22521037

SN - 1527-5299

VL - 18

SP - 291

EP - 294

JO - Congestive Heart Failure

JF - Congestive Heart Failure

IS - 5

ER -

Left ventricular assist device as bridge to recovery for anthracycline-induced terminal heart failure

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater